Project Grant HT94252410602
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$563K
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
This is a $538,218 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to study the role of ERR-alpha in skeletal muscle regeneration and functional recovery for Duchenne muscular dystrophy. The project aims to advance scientific understanding and develop potential treatments for this debilitating...
<p>The Defense Health Agency awarded Wake Forest University Health Sciences a $542,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund high-throughput screening to identify lipid nanoparticles effective for systemic delivery to tissues affected by Duchenne muscular dystrophy. The research is scheduled to be completed by September 29, 2025.</p>
The federal Project Grant award, valued at $405,341.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by the Children's Research Institute in Washington, D.C. The grant aims to advance the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). The Children's Research Institute, a prominent pediatric research organization, will leverage...
This $953,125 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in nonambulatory individuals with Duchenne muscular dystrophy. The research project will run from November 1, 2024 to October 31, 2027 and aims to advance understanding of neurodegenerative diseases...
This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to the University of California, Los Angeles (UCLA) to develop 3D-Bridge antisense oligonucleotides and a stem cell-targeting modality for skipping exons of Duchenne muscular dystrophy. The award period is from July 1, 2024 to June 30, 2026. Through this grant, UCLA will leverage its research and administrative capabilities to advance novel therapeutic...
This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This federal Project Grant award, valued at $657,945, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports a 3-year research project at Carleton University in Ottawa, Canada, focused on predicting differential quality of life outcomes for Duchenne muscular dystrophy (DMD) patients based on distinct corticosteroid treatment regimens. The study will leverage serum proteome and steroid hormone profiling to...